Unique effects of nicotine across the lifespan

Michelle Ren a, *, Shahrdad Lotfipour a, b, c, Frances Leslie a

a Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA
b Department of Emergency Medicine, School of Medicine, University of California, Irvine, Irvine, CA, USA
c Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Irvine, Irvine, CA, USA

A R T I C L E   I N F O

Keywords:
Nicotinic acetylcholine receptors
Developmental nicotine exposure
Prenatal
Perinatal
Adolescence
Aging

A B S T R A C T

Smoking remains the leading cause of preventable death in the United States. Although combustible cigarettes are largely being replaced by tobacco-free products, nicotine use continues to increase in vulnerable populations, including youth, adolescents, and pregnant women. Nicotine exerts unique effects on specific brain regions during distinct developmental periods due to the dynamic expression of nicotinic acetylcholine receptors (nAChRs) throughout the lifespan. Nicotine exposure is a health concern not only for adults but also has neurotoxic effects on the fetus, newborn, child, and adolescent. In this review, we aim to highlight the dynamic roles of nAChRs throughout gestation, adolescence, and adulthood. We also provide clinical and preclinical evidence of the neurodevelopmental, cognitive, and behavioral consequences of nicotine exposure at different developmental periods. This comprehensive review highlights unique effects of nicotine throughout the lifespan to help elucidate interventions and public health measures to protect sensitive populations from nicotine exposure.

1. Introduction

Use of nicotine products is an unrelenting public health concern, as smoking is the leading cause of preventable death in the United States (U.S.) (Centers for Disease Control and Prevention, 2021). Although the rate of smoking combustible cigarettes has decreased in the last decade, nicotine exposure has risen substantially due to the increased popularity of tobacco-free, electronic nicotine delivery systems (e.g. electronic cigarettes, vaping), primarily among youth and teenagers (Miech et al., 2019). Additionally, pregnant and lactating women are increasingly replacing tobacco products with e-cigarettes even though these may not be safer for the developing offspring (Kim and Oancea, 2020; Wagner et al., 2017). Nicotine, the primary psychoactive component of tobacco, exerts unique effects on specific brain regions during distinct developmental periods (Dwyer et al., 2009). Nicotine exposure is thus not only a health concern for adults but also has neurotoxic effects on the fetus, newborn, child, and adolescent.

Nicotine binds to nicotinic acetylcholine receptors (nAChRs), which regulate various aspects of brain development. The effects of nicotine are highly dependent on timing of exposure, with detrimental effects of drug exposure more pronounced prior to adulthood due to the incomplete maturation of neural circuitry in the developing brain. Various animal studies (i.e. lambs, rats, and mice) reveal that gestational nicotine exposure contributes to reduced pulmonary function, auditory processing defects, and impaired cardiorespiratory function during infancy, as well as cognitive and behavioral deficits later in life (Samford and Hawkins, 1996; Franke et al., 2007, 2008; Huang et al., 2007a, 2007b; Karlsson et al., 2004; Neff et al., 2003; Paz et al., 2007). Further, adolescent nicotine exposure may cause deficits in working memory and attention, and alterations in reward processing that increase the potential for subsequent drug abuse and addiction (Ren and Lotfipour, 2019; Leslie, 2020; Fleming et al., 1989; Lai et al., 2000; Nkansah-Amankra and Minelli, 2016).

In this review, we aim to highlight the dynamic roles of nAChRs throughout the lifespan and provide clinical and preclinical evidence of the neurodevelopmental, cognitive, and behavioral consequences of nicotine exposure at different developmental periods. This comprehensive review highlights unique effects of nicotine throughout the lifespan to help elucidate interventions and public health measures to protect sensitive populations from nicotine exposure.

2. Materials and methods

We conducted a systematic search of the literature related to
developmental nicotine exposure published before July 2021. We used the electronic databases of PubMed and Google Scholar for research articles published in English between January 1971 and July 2021. Articles or book chapters were included in the review if they discussed nicotine exposure during gestation, childhood, adolescence, or aging. We grouped studies together according to their methodological similarities, so findings without substantial support or reproducibility (i.e., fewer than 5 comparable studies) were excluded. Following exclusion and careful analysis of studies based on key results, limitations, suitability of the methods to test the initial hypothesis, and quality and interpretation of the results obtained, 156 references were selected. The use of three reviewers and two extensive electronic databases allows for a widespread range of research articles, which maximizes scientific credibility and minimizes potential bias.

3. Results

3.1. Pharmacology

Nicotine is the primary psychoactive constituent in tobacco products and binds to nAChRs, which are pentameric ligand-gated ion channels composed of α and β subunits (α7, 9–10; β1–4). nAChRs are widely distributed throughout the human and rodent brain and periphery and are critical in the processes of the neuromuscular junction, neurotransmitter release, brain maturation, reward processing, and cognition (Brodie and Leslie, 1999; Campbell et al., 2010; Gotti et al., 2006; Gotti and Clementi, 2004; McGehee, 1999; Pentel et al., 2006; Zoli et al., 1995). Nicotine can both activate and desensitize nAChRs that mediate the physiological effects of acetylcholine (Dani, 2001). A developmental regulation of nAChR function occurs in the brain, with differing modulation of neurotransmitter release from gestation through adulthood (O'Leary and Leslie, 2003). This shift in nAChR regulation is dependent on the properties of nAChRs across the lifespan. A comprehensive review of nAChR regulation of developing catecholamine systems and its implications for numerous disease states has been provided previously (Azam et al., 2006). Notably, age-dependent changes in nAChR pharmacology are important in the development of the cerebellum and sensory cortices, as well as dopamine release from the ventral midbrain and noradrenergic release from the hippocampus.

3.2. Prenatal and early postnatal development

Prenatal nicotine exposure continues to be a concern for pregnant women who have increasingly replaced smoking with electronic nicotine products or patches due to the misconception of a safer smoking alternative (Baeva-Loya et al., 2014). Nicotine readily crosses the placental barrier and can be found in the amniotic fluid and umbilical cord of neonates (Luck et al., 1985). Nicotine exposure during pregnancy results in increased high affinity nAChR binding in the fetal and neonatal brain, providing evidence that nicotine reaches the fetal brain and upregulates nAChRs as it does in adult rats (Navarro et al., 1989; Nguyen et al., 2003; Pentel et al., 2006; Slotkin et al., 1987a, 1987b). Numerous reports in humans have revealed the toxic properties of nicotine exposure during pregnancy on the offspring’s brain and behavior (Lotzpour et al., 2014; McGrath-Morrow et al., 2020).

nAChRs are involved in critical early developmental processes, including neurite outgrowth, cell survival, proliferation, differentiation, and neurogenesis (Dani, 2001). Activation and/or desensitization of nAChRs via nicotine exposure during gestation may disrupt brain programming and plasticity into postnatal life (Slotkin et al., 1987a, 1987b). Furthermore, use of e-cigarettes (Regan et al., 2021) or combustible cigarettes (Kyrklund-Blomberg et al., 2005; Mitchell and Milerad, 2006; Ozturk et al., 2016; Perry et al., 2019; US Department of Health and Human Services, 2014) during pregnancy is associated with pregnancy complications, risks of preterm delivery, lower birth weight, cleft palate, and sudden infant death syndrome.

In utero nicotine exposure in both humans (Ernst et al., 2001; Eskenazi et al., 1995; Regan and Pereira, 2021) and rodents (Paulson et al., 1993; Roy and Sabherwal, 1994; Slotkin et al., 1987a, 1987b) adversely affects prenatal and postnatal growth and increases the risk of fetal mortality and morbidity. Prenatal nicotine exposure affects cardiovascular and lung function and growth of the developing mouse fetus, as nicotine adversely affects fetal hemodynamics acutely and chronically in early pregnancy, potentially leading to fetal tissue hypoxia and intrauterine growth restriction (Aoyagi et al., 2020). Prenatal nicotine also interferes with male testosterone production during the perinatal surge in humans (Fried et al., 2001) and rodents (Sarasin et al., 2003), and these acute endocrine effects of nicotine during gestation may be long-lasting (Lichtensteiger and Schlumpf, 1985).

Gestational nicotine exposure also impacts the developing brain at doses that do not delay general growth (Slotkin, 1998), which can be observed through motor, sensory, cognitive, and behavioral deficits in infants and toddlers (Ernst et al., 2001; Fergusson et al., 1998; Fuentes-Cano et al., 2020; Gusella and Fried, 1984; Lichtensteiger et al., 1988; Weissman et al., 1999; Zeld et al., 2018). Smoking during pregnancy is now considered to be the primary cause of sudden infant death syndrome, resulting from compromised development of cardiac and respiratory brainstem centers (Slotkin and Seidler, 2011; Vivekanandarajah et al., 2019; Zhang and Wang, 2013). Additionally, in utero exposure to nicotine produces decreased synaptic plasticity and developmental effects on the medial prefrontal cortex and nucleus accumbens in rodents, which is observed through attention-deficit/hyperactivity disorder, conduct problems, depression, anxiety, externalizing behavior, and substance use in the offspring (Table 1; Franke et al., 2008; Dwyer et al., 2019).

The prenatal period in humans refers to the entire duration of human gestation (3 trimesters or 9 months). However, because rodents are born at an earlier stage of brain maturation than humans, prenatal nicotine exposure in rats or mice only translates to exposure during the first two trimesters of human gestation (Bayer et al., 1993; Quinn, 2005). The first twelve days of rodent development are comparable to the third trimester of human gestation (Quinn, 2005), so nicotine exposure during the early postnatal period in rodents is also studied for a comprehensive understanding of human prenatal nicotine exposure. During this time, the brain is rapidly growing, and development of the cortex, hippocampus, and cerebellum are just beginning (Bayer et al., 1993; Dobbing, 1971). There is a transient appearance of cholinergic markers, including nAChRs, during the postnatal development of these regions (Brodie and Leslie, 1999; Clos et al., 1989; Winzer-Serhan and Leslie, 2005). Disruption of the cholinergic system during this period via early postnatal nicotine exposure impairs development of the cortex and hippocampus, and produces permanent changes in cortical circuitry that result in deficiencies in somatosensory, auditory and cognitive processing (Aramakis et al., 2000; Heath et al., 2010; Hsieh et al., 2002; Huang et al., 2007a, 2007b; Liang et al., 2006). Human studies have also shown similar deficiencies in central auditory processing in school-age children prenatally exposed to cigarette smoke (McCartney et al., 1994).

3.3. Adolescence

Adolescence is characterized by significant hormonal, psychosocial, and neural changes in rodents (postnatal day (PND) 28–42) and humans (12–18 years of age) (Spear, 2006). During this sensitive maturation period, the brain is remarkably vulnerable to the harmful effects of nicotine, which is especially critical given that adolescence is also the age of peak onset of nicotine use (Miech et al., 2019).

Animal studies consistently demonstrate the unique effects of nicotine exposure on the adolescent brain, including increased number and activity of nAChRs in reward-related brain regions (Doura et al., 2008; Kota et al., 2007), as well as increased nicotine-induced dopamine release in limbic regions (Azam et al., 2007; Corongiu et al., 2020). Behaviorally, adolescents exposed to nicotine display increased...
Table 1
Summary of behavioral findings and molecular mechanisms of prenatal, adolescent, or adult nicotine exposure in rodents, and relevant human studies. G: Gestational day, P: Postnatal day, i.p.: intraperitoneal, i.v.: intravenous, s.c.: subcutaneous.

| Nicotine exposure (dose, route of administration, duration) | Rat/mouse, strain, and age of exposure | Behavioral findings and age of evaluation | Molecular mechanisms | Reference(s) | Relevant human studies |
|-------------------------------------------------------------|--------------------------------------|------------------------------------------|---------------------|-------------|-----------------------|
| Prenatal exposure 3 mg/kg/day, s.c., 2 weeks                | Sprague-Dawley rats, prenatal (G4–18) | Increased cocaine self-administration in nicotine-exposed vs. saline-exposed offspring (P32–37) Increased cocaine-induced locomotor activity in nicotine-exposed vs. saline-exposed offspring (P32) | Increased cocaine-induced c-fos mRNA expression in the nucleus accumbens Altered corticollimbic dopamine system development (increased dopamine in prefrontal cortex) | Franke et al., 2008 Lotfipour et al., 2014 | |
| Adolescence: drug-related behavior 60 μg/kg, i.v., 4 days   | Sprague-Dawley rats, adolescence (P28–31) | Increased self-administration of cocaine in adolescent rats pretreated with nicotine vs. saline-treated adolescents and both saline- and nicotine-treated adults (P32) | D2 receptors, microglia (CX3CL1 receptor) activation | Dao et al., 2011 Fleming et al., 1984; Lai et al., 2006; Nakash-Amankra and Minelli, 2016 | |
| 0.4 mg/kg/day, i.p., 10 days                               | Sprague-Dawley rats, adolescence (P34–43) | Exposure to nicotine during perinatal period, but not a similar exposure in the postadolescent period, increased intravenous self-administration of nicotine (P75+) | Increase in gene expression of the DA neuron-specific subunits (α5 and α6) and of the β2 subunit from adolescent nicotine exposure | Adriani et al., 2003 | |
| 0.16 or 0.64 mg/kg, s.c., 2 weeks                          | Sprague-Dawley rats, adolescence (P35–50) | Increased methamphetamine intake in adulthood | None evaluated | Pipkin et al., 2014 | |
| 0.4 mg/kg nicotine/day, i.p., 7 days                       | Sprague-Dawley rats, adolescence (P30–36) | Long-term increase in cocaine reinforcement, lack of sensitization to nicotine's locomotor-activating effects (P37); opposite findings in adults | Adolescent nicotine treatment increased dopamine transporter densities and decreased serotonin transporter densities; in adults, no change in dopamine transporter, dopamine D1 or D2 receptor, or serotonin transporter densities | Collins and Izenwasser, 2004; Collins et al., 2004; Reed and Izenwasser, 2017 | |
| 0.1, 0.5, or 1 mg/kg, s.c., 2/day for either 1 (acute) or 7 (repeated) days | CD-1 mice, adolescence (P28–34 or P50–56) | Adults exposed to nicotine during early but not late adolescence had increased preference for cocaine, morphine, and amphetamine during adulthood (P70+) | Accumulation of deltafosB in the nucleus accumbens | Alajaji et al., 2016 | |
| 0.4 mg/kg, i.p., 14 days                                    | Long-Evans rats, adolescence (P28–42) | Adults exposed to nicotine during adolescence had increased ethanol self-administration compared to adolescent and adult saline exposure and adult nicotine exposure | | | |
| Adolescence: attention 0.4 mg/kg, s.c., 3/day for 10 days   | Wistar rats, adolescence (P34–43) | Impaired measures of attention in adulthood (P70+) | Reduced mGluR2 protein and function on presynaptic terminals of PFC glutamatergic synapses, enhanced releasability of dopamine in the mPFC | Crounse et al., 2009; Crounse et al., 2011; Foulds et al., 1996; Grobe et al., 1998; Xu et al., 2005 | |
| Adolescence: mood and anxiety 0.03, 0.1, or 0.3 mg/kg/day, i.p., 10 days | CD-1 mice, adolescence (P36–48 or P49–61) | Acute nicotine administration had opposite effects on anxiety in adolescents (P48) and adults (P61) | A dose-dependent reduction of GluR2/3 immunoreactivity in the striatum and hippocampus 2 months after a pretreatment with nicotine during mid-adolescence | Adriani et al., 2004 Newcombe et al., 2021 | |
| 0.16, 0.32, or 0.64 mg/kg, s.c., 2×/day for 15 consecutive days | Sprague-Dawley rats, adolescence (P30–44, P34–44) | Increased depression-like and anxiety-like behaviors in adulthood (P70+) | Prefrontal cortical neuronal hyperactivity, selective PFC downregulation of B1R expression levels, increased phosphorylation of ERK 1–2 | Iniguez et al., 2009; Jobson et al., 2019 | |
| 0.4 mg/kg, s.c., 3×/day for 10 consecutive days             | | | | |
| Aging 100 μg/ml in 2% saccharin, oral, 14 days             | C57BL/6J mice, adulthood (P60+) | Nicotine prevents the conversion of APP-α to APP-β and lowers the secretion of APP-β | Nicotine treatment enhances expression of APP and APLP2 proteins in SH-SY5Y cells The proposed mechanism is a central | Gutala et al., 2006; Utsuki et al., 2002 | |

(continued on next page)
rewarding effects of drugs of abuse (Leslie, 2020; Ren and Lotfipour, 2019; Yuan et al., 2015), decreased attention and other learning/memory deficits (Counotte et al., 2009, 2011; Holliday and Gould, 2016a, 2016b; Kutlu et al., 2018; Portugal et al., 2012), and emotional dysregulation (Adriani et al., 2004; Holliday and Gould, 2016a, 2016b; Iniguez et al., 2009; Jobson et al., 2019; Slaweki et al., 2003; Smith et al., 2006). This is due largely in part by increased activity in reward-related centers in the brain via dopaminergic, serotonergic, cholinergic, and inflammatory mechanisms (Table 1). The increased reward induced by nicotine may lead to subsequent abuse of other drugs, including nicotine itself, alcohol, cocaine, methamphetamine, and fentanyl (Alajaji et al., 2016; Cardenas et al., 2021; Cole et al., 2019; Collins and Izenwasser, 2004; Collins et al., 2004; Dau et al., 2011; Linker et al., 2020; McQuown et al., 2009, 2007; Pipkin et al., 2014; Reed and Izenwasser, 2017; Thomas et al., 2018). These nicotine-induced changes in the brain and behavior are long-lasting into adulthood.

Adolescent nicotine exposure is predictive of nicotine dependence in adulthood, as adolescent rodents show increased nicotine reward (Adriani et al., 2003; Torres et al., 2008), reduced aversion (O’Dell et al., 2006; Stram et al., 2006; Torres et al., 2008), and enhanced sensitivity to withdrawal effects (Dierker and Mermelstein, 2010; DiFranza and Lew, 1995; Zhan et al., 2012) as compared to adults. There is significant clinical evidence supporting that individuals who begin smoking during adolescence are more likely to have trouble quitting than those who start as adults (Breslau and Peterson, 1996; Cengelli et al., 2012; Chen and Millar, 1998; DiFranza and Lew, 1995; Kandel and Chen, 2000; Khudery et al., 1999). This is further reinforced by the report that 90% of adult smokers started before age 18 (Substance Abuse and Mental Health Services Administration, 2014; US Department of Health and Human Services, 2014). Teen e-cigarette users are more likely to report dependence signs and be daily users if they use high nicotine content pods, such as Juul (Boykan et al., 2019).

Further, nicotine exposure differentially impacts males and females during adolescence. Females are more vulnerable to tobacco use than males, as female versus male adolescent rodents self-administer greater amounts of oral or intravenous nicotine (Chen et al., 2007; Klein et al., 2004; Lynch, 2009; Sanchez et al., 2014), show impaired rearing and locomotor activity following adolescent nicotine exposure (Trauth et al., 2000), and are more sensitive to behavioral deficits and hippocampal cell damage from nicotine withdrawal (Xu et al., 2003). Sex differences in nicotine responses may be due to gonadal steroid-mediated sexual differentiation of the brain, as nAChRs and major neurotransmitter systems are modulated by different sex hormones throughout development (Azam et al., 2007; Cross et al., 2017; Pogun and Yararbas, 2009; Slotkin et al., 2007).

### 3.4. Aging

The adult brain is no longer considered to be developing; rather, the aging brain experiences a gradual loss of neural circuits and synaptic plasticity that is associated with an age-dependent decline in cognitive function (Yankner et al., 2008). Clinical and preclinical data support a neuroprotective effect of nicotine during adulthood and senescence, preventing the onset of degenerative neurological disorders, such as Alzheimer’s dementia and Parkinson’s Disease (Ferrea and Winterer, 2009). Nicotine use in humans also positively influences learning, memory, and attention, and improves mood, stress regulation, and anxiety (Feldner et al., 2007; Foulds et al., 1996; Gehricke et al., 2007; Grobe et al., 1998; Marshall et al., 2008; Metcalfe et al., 2003; Xu et al., 2005). However, the potential benefits of nicotine use in either cigarettes or e-cigarettes are greatly outweighed by its negative consequences, including risk of addiction, cancer, heart disease, high blood pressure, respiratory infections, and gastrointestinal distress (Mishra et al., 2015; US Department of Health and Human Services, 2014). The debate against nicotine’s neuroprotective versus neurotoxic effects is complex and appears to involve regulation mechanisms of nAChRs and interactions between nicotine and other central nervous system neurotransmitters.

The observation of lower rates of dementia in smokers has prompted further investigation into the role of nicotinic effects in neurodegenerative diseases (Table 1). Alzheimer’s disease is characterized by an aggregation and precipitation of amyloid precursor proteins (APP) in the form of plaques, which are a result of overproduction and/or altered metabolism of APP-β. α7-containing nAChRs are present in the plaques, and nicotine prevents the conversion of APP-α to APP-β and lowers the secretion of APP-β (Gutala et al., 2006; Utsuki et al., 2009). The proposed mechanism is a central role of α4β2 and α7 nAChRs in enhancing the release of neuroprotective APP-α and lowering APP-β production (Mousavi and Hellström-Lindahl, 2009).

A U.S. government-funded veteran’s study found that smoking reduced Parkinson’s deaths by 64% (Dorn, 1959). Nicotine promotes neuron survival and partially protects from Parkinson’s by suppressing SIRT6 in mice (Nicholatos et al., 2018). The neuroprotective effects of nicotine have been observed particularly in the hippocampus,
entorhinal cortex, and neocortex (Perry et al., 2006; Zeid et al., 2018). In contrast, nicotine has been shown to have neuroinflammatory effects in adolescence that switch to neuroprotection in adulthood (Linker et al., 2020). These findings may suggest interventions using neuronal nAChRs as novel targets for inflammation and neuroprotection in adults (Benchferich, 2009), with a strong contraindication at younger ages.

3.5. Vaping versus smoking

Replacing traditional combustible cigarettes with e-cigarettes (vaping) reduces the exposure to tobacco’s carcinogens and is substantially less harmful than smoking (George et al., 2019; McNeill et al., 2018, 2020; National Academies of Sciences, Engineering, and Medicine, 2018). However, vaping also carries significant health risks, including addiction, metal exposure, inhalation of toxic solvents, and vaping-associated lung injury (Perrine et al., 2019; Schmidt, n.d.). Furthermore, its effectiveness in reducing or eliminating smoking is controversial (Dai and Leventhal, 2019; El Dib et al., 2017). Clinical data suggest that smokers vape to maintain their habit instead of quitting entirely and have increased total nicotine use despite a reduction in cigarette smoking (Hajek et al., 2019; Martínez et al., 2020; Rehan et al., 2018). Although vaping may promote harm reduction for smoking, nicotine exposure is a concern in the youth, and adolescents have demonstrated an increased attraction to electronic cigarettes due to vape flavors, belief that vaping is harm-free, self-help, and societal pressure (Leventhal et al., 2019; Newcombe et al., 2021). There is increasing evidence in humans and animals that e-cigarette use is harmful to youth and the unborn child (Pierce et al., 2021; Regan et al., 2021).

4. Conclusion

Due to the dynamic expression of the cholinergic system throughout the lifespan, chronic and acute nicotine exposure differentially affect brain structure, function, and behavior in the perinatal period, adolescence, and adulthood. The patterns of expression and pharmacological and physiological properties of nAChRs are unique to the developmental period. Nicotine exposure during the perinatal period disrupts general growth, cardiovascular and lung function, the endocrine system, motor function, reward, and attention. Adolescent nicotine exposure enhances susceptibility to addiction, impulsivity, and mood disorders. While nicotine exposure during adulthood may not have the apparent adverse consequences on the brain seen in earlier critical developmental windows, the health risks associated with tobacco and nicotine use are equally destructive. The potential neuroprotective effects of nicotine in senescence comprise an interesting field of research to explore further.

Funding

This work was supported by the University of California Irvine (UCI) NIDA T32 training grant (T32DA050558) (MR), UCI School of Medicine start up fund (SL), UCI Institute for Clinical and Translational Sciences (ICTS) Pilot Studies Program (NIH/NCATS) (SL), Helping End Addiction start up fund (SL), UCI Institute for Clinical and Translational Sciences NIDA T32 training grant (T32DA050558) (MR), UCI School of Medicine Funding.

References

Adriani, W., Spijker, S., Deroche-Gamonet, V., Laviola, G., Le Moal, M., Smit, A.B., Half, A.W., Berg, D.K., 2010. Endogenous signaling through α7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus. J. Neurosci. 30, 8734-8744.

Adriani, W., Spijker, S., Deroche-Gamonet, V., Laviola, G., Le Moal, M., Smit, A.B., Half, A.W., Berg, D.K., 2010. Endogenous signaling through α7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus. J. Neurosci. 30, 8734-8744.

Adriani, W., Spijker, S., Deroche-Gamonet, V., Laviola, G., Le Moal, M., Smit, A.B., Half, A.W., Berg, D.K., 2010. Endogenous signaling through α7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus. J. Neurosci. 30, 8734-8744.

Bayer, S.A., Altman, J., Russo, R., Zhang, X., 1993. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxol. Park. For. South 14, 83-144.

Benchferich, M., 2009. Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance. Acta Pharmacol. Toxicol. 99, 702-714. https://doi.org/10.1111/j.1744-0596.2009.02957.x.

Boykan, R., Goniewicz, M.L., Messina, C.R., 2019. Evidence of nicotine dependence in adolescent versus adulthood: differences in nicotine use associated with age. Drug Alcohol Depend. 200, 349-359. https://doi.org/10.1016/j.drugalcdep.2019.01.043.

Brezina, N., Peterson, E.L., 1996. Smoking cessation in young adults: age at initiation of cigarette smoking and other suspected influences. Am. J. Public Health 86, 214-220.

Breid, R.S., Leslie, F.M., 1999. The α7 nicotinic acetylcholine receptor in neuronal plasticity. Mol. Neurobiol. 20, 1-16.

Campbell, N.R., Fernandes, C.C., Half, A.W., Berg, D.K., 2010. Endogenous signaling through α7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus. J. Neurosci. 30, 8734-8744.

Cardenas, A., Martinez, M., Mejia, A.S., Lotfipour, S., 2021. Early adolescent subchronic low-dose nicotine exposure increases subsequent cocaine and methamphetamine self-administration in Sprague-dawley rats. Behav. Pharmacol. 32, 86-91.

Cengelli, S., O’Loughlin, J., Lauzon, B., Cornuz, J., 2012. A systematic review of longitudinal population-based studies on the predictors of smoking cessation in adolescent and young adult smokers. Tob. Control. 21, 355-362.

Centers for Disease Control and Prevention, 2021. Smoking and Tobacco Use. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/ovd/smoking.htm.

Chen, J., Millar, W.J., 1998. Age of smoking initiation: implications for quitting. Health Behav. Policy. Res. 5, 39-48.

Chen, H., Matta, S.G., Sharp, B.M., 2007. Acquisition of nicotine self-administration in adolescent rats given prolonged access to the drug. Neuropharmacology 502, 75-85. https://doi.org/10.1016/j.ejphar.2004.08.039.
A retrospective analysis of dual users. Nicotine Tob. Res. 22, 764–770. https://doi.org/10.1093/ntr/mrt434.

McCartney, J.S., Prather, A., Watkins, T., Bakken, B., 1994. Central auditory processing in school-aged children prenatally exposed to cigarette smoke. Neurotoxicol. Teratol. 16, 269–276.

McGhee, D.S., 1999. Molecular diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Cell. Dev. Biol. 15, 563–586. https://doi.org/10.1146/annurev.cellbio.15.1.563.

McGrath-Morrow, S.A., Gorzkowski, J., Groner, J.A., Rule, A.M., Wilson, K., Tanski, S.E., Collaco, J.M., Klein, J.D., 2020. The effects of nicotine on development. Pediatrics 145, e20191346. https://doi.org/10.1542/peds.2019-1346.

McNeil, A., Brosa, L.S., Calder, R., Biald, L., Robson, D., 2018. Evidence Review of E-cigarettes and Heated Tobacco Products 2018. A Report Commissioned by Public Health England. 6, Public Health England, London.

Menon, N., Brosa, L., Laidre, R., Biald, L., Robson, D., 2020. Vaping in England: An Evidence Update Including Mental Health and Pregnancy, March 2020. Public Health England, London, UK.

McQuown, S.C., Dao, J.M., Belluzzi, J.D., Leslie, F.M., 2009. Age-dependent effects of nicotine on adolescent development. J. Dev. Behav. Pediatr. 30, 539–545. https://doi.org/10.1097/DBP.0b013e3181a5c487.

Mousavi, M., Hellström, A., Chaturvedi, P., Datta, S., Sinukumar, S., Joshi, P., Garg, A., 2015. Harmful use of tobacco and tobacco products and progression to daily cigarette smoking. Pediatrics 147, e20002512. https://doi.org/10.1542/peds.2000-2512.

Pigott, A.J., Kaplan, G.J., Plant, C.P., Eaton, S.E., Gil, S.M., Zavala, A.R., Crawford, C.A., 2004. Nicotine exposure beginning in adolescence enhances the acquisition of methamphetamine self-administration, but not methamphetamine–primed reinstatement in male rats. Drug Alcohol Depend. 74, 83–91. https://doi.org/10.1016/j.drugalcdep.2003.09.015.

Pogon, S., Yarasheski, G., 2014. Sex differences in nicotine action. Nutrition. 37, 261–269. https://doi.org/10.1016/j.nut.2014.05.002.

Porter, J., Klein, J., 2003a. Effects of nicotine on the cardiovascular system. Circulation 107, 1193–1199. https://doi.org/10.1161/01.CIR.0000054408.28166.05.

Porter, J., Klein, J., 2003b. Effects of nicotine on the cardiovascular system. Circulation 107, 1193–1199. https://doi.org/10.1161/01.CIR.0000054408.28166.05.

Porter, J., Klein, J., 2003b. Effects of nicotine on the cardiovascular system. Circulation 107, 1193–1199. https://doi.org/10.1161/01.CIR.0000054408.28166.05.

Quinn, R., 2005. Comparing rat’s to human’s age: how old is my rat in people years? Nutrition 21, 775–777. https://doi.org/10.1016/j.nut.2005.04.002.

Reed, S.C., Inneswar, S., 2017. Nicotine produces long-term increases in cocaine reinforcement in adolescent but not adult rats. Brain Res. 1654, 165–170.

Regan, A.K., Pereira, G., 2021. Patterns of combative and electronic cigarette use during pregnancy and associated pregnancy outcomes. Science 31, 13508–13508.

Regan, A.K., Bombard, J.M., O’Hegarty, M.M., Smith, R.A., Tong, V.T., 2021. Adverse birth outcomes associated with preconception and prenatal electronic cigarette use. Obstet. Gynecol. 10–1097.

Rehan, H.S., Manji, H., Hungin, A.P., 2018. Vaping versus smoking: a quest for efficacy and safety of e-cigarettes. Curr. Drug Saf. 13, 92–101.

Ren, M., Loftspur, S., 2019. Nicotine gateway effects on adolescent substance use. West J. Emerg. Med. 20, 696.

Roy, T., Sabharwal, V., 1994. Effects of prenatal nicotine exposure on the morphogenesis of somatosensory cortex. Neurotoxicol. Teratol. 16, 411–421.

Shea, S.G., Moore, A.F., Brown, D.E., 2006. Differences in the effect of wheel running on subsequent nicotine-seeking in a rat adolescent-onset self-administration model. Psychopharmacology 231, 1753–1762.

Sarasin, A., Schlumpf, M., Müller, M., Fleischmann, I., Lauber, M.E., Lichtensteiger, W., 2000. Adrenal-mediated rather than direct effects of nicotine as a basis of altered steroid synthesis in fetal and neonatal rat. Reprod. Toxicol. 17, 153–162. https://doi.org/10.1016/S0890-6238(02)00119-3.

Schmid, Silke n.d. Vaper, beware: the unique toxicological profile of electronic cigarettes. Environ. Health Perspect. 128, 052601. https://doi.org/10.1289/ehp.1608628.

Sharma, R.C., Kim, Y., 2016. “Gateway hypothesis” and early drug use: additional findings from tracking a population-based sample of adolescents to adulthood. Prev. Med. Rep. 4, 134–141.

O’Dell, L.E., Buckner, L., Smith, R.P., Westra, S.H., Parsons, L.H., Merves, M.L., Goldberger, B.A., 2003. Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine. Psychopharmacology 166, 201–208.

Sawle, C.J., Gilder, A., Roth, J., Eben, C.L., 2003. Increased anxiety-like behavior in adult rats exposed to nicotine as adolescents. Pharmacol. Biochem. Behav. 75, 355–361.

Slotkin, T.A., 1998. Fetal nicotine or cocaine exposure: which one is worse? J. Pharmacol. Exp. Ther. 285, 931.

Slotkin, T.A., Seidler, F.J., 2011. Mimicking maternal smoking and pharmacotherapy of preterm labor: fetal nicotine exposure enhances the effect of late gestational administration of an anti-cocaine regimen. Teratology 83, 434–440.

Slotkin, T.A., Orband-Miller, L., King, Q., 1987. Development of [3H] nicotine binding sites in brain regions of rats exposed to nicotine prenatally via maternal injections or by drinking water. Brain Res. 40, 227–237.

Spieker, L.C., 2000. The rewarding effects of nicotine on neuronal nicotine exposure in neonatal development: selective actions on central and peripheral catecholaminergic pathways. Brain Res. Bull. 44, 591–601.

Slotkin, T.A., Mackillop, E.A., Rudder, C.L., Byrde, L.T., Tate, C.A., Seidler, F.J., 2007. Permanent, sex-selective effects of prenatal or adolescent nicotine exposure, separately or sequentially, in rat brain regions: indices of cholinergic and serotonergic synaptic function, cell signaling, and neural cell number and size at 6 months of age. Neuropsychopharmacology 32, 1082–1097. https://doi.org/10.1038/sj.npp.1301237.

Smith, M.N., McDonald, C.G., Bergstrom, H.C., Brclwmaier, J.M., Eppolito, A.K., Wheeler, T.L., Falco, A.M., Smith, R.F., 2006. Long-term changes in fear conditioning and anxiety-like behavior following nicotine exposure in adult versus perinatally exposed rats. Pharmacol. Biochem. Behav. 89, 91–97.

Spear, L.P., 2000. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 24, 417–463.

Substance Abuse and Mental Health Services Administration. 2014. Mental Health Services Administration. 2013. The National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SAMHSA) 14-883, 2014. Subst. Abuse Ment. Health Serv. Admin. Rockv. MD.

Thomas, A.M., Ostrovoumov, A., Kimmey, B.A., Taormina, M.B., Holden, W.M., Kim, K., Brown-Mangum, T., Davis, L.A., 2018. Adolescent nicotine exposure alters GABA(A) receptor signaling in the ventral tegmental area and increases adult ethanol self-administration. Cell Rep. 23, 68–77. https://doi.org/10.1016/j.celrep.2018.03.030.

Torros, O.V., Tejeda, H.A., Natalivon, I.A., O’Dell, L.E., 2008. Enhanced vulnerability to the rewarding effects of nicotine during the adolescent period of development. Pharmacol. Biochem. Behav. 90, 658–663.

Tzartos, S., Cohen, H., Ballard, C., McKee, I., 2017. Persistent and delayed behavioral changes after nicotine treatment in adult rats. Brain Res. 1672, 611–617.

US Department of Health and Human Services. 2014. Mental Health.
Utsuki, T., Shoaib, M., Holloway, H.W., Ingram, D.K., Wallace, W.C., Haroutunian, V., Sambamurti, K., Lahiri, D.K., Greig, N.H., 2002. Nicotine lowers the secretion of the Alzheimer’s amyloid β-protein precursor that contains amyloid β-peptide in rat. J. Alzheimers Dis. 4, 405–415.

Vivekanandarajah, A., Waters, K.A., Machaalani, R., 2019. Cigarette smoke exposure effects on the brainstem expression of nicotinic acetylcholine receptors (nAChRs), and on cardiac, respiratory and sleep physiologies. Respir. Physiol. Neurobiol. 259, 1–15.

Wagner, N.J., Camerota, M., Propper, C., 2017. Prevalence and perceptions of electronic cigarette use during pregnancy. Matern. Child Health J. 21, 1655–1661.

Weissman, M.M., Werner, V., Wickramaratne, P.J., Kandel, D.B., 1999. Maternal smoking during pregnancy and psychopathology in offspring followed to adulthood. J. Am. Acad. Child Adolesc. Psychiatry 38, 892–899.

Winzer-Serhan, U.H., Leslie, F.M., 2005. Expression of α5 nicotinic acetylcholine receptor subunit mRNA during hippocampal and cortical development. J. Comp. Neurol. 481, 19–30.

Xu, Z., Seidler, F.J., Tate, C.A., Garcia, S.J., Slikker Jr., W., Slotkin, T.A., 2003. Sex-selective hippocampal alterations after adolescent nicotine administration: effects on neurospecific proteins. Nicotine Tob. Res. 5, 955–960.

Xu, J., Mendrek, A., Cohen, M.S., Monterosso, J., Rodriguez, P., Simon, S.L., Brody, A., Jarvik, M., Domier, C.P., Olmstead, R., 2005. Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence. Biol. Psychiatry 58, 143–150.

Yankner, B.A., Lu, T., Loehr, P., 2008. The aging brain. Annu. Rev. Pathol. Mech. Dis. 3, 41–66. https://doi.org/10.1146/annurev.pathmechdis.2.010506.092044.

Yuan, M., Cross, S.J., Loughlin, S.E., Leslie, F.M., 2015. Nicotine and the adolescent brain. J. Physiol. 593, 3397–3412. https://doi.org/10.1113/JP270492.

Zeid, D., Kathu, M.G., Gould, T.J., 2018. Differential effects of nicotine exposure on the hippocampus across lifespan. Curr. Neuropharmacol. 16, 388–402. https://doi.org/10.2174/1570159X15666170714092436.

Zhan, W., Dierker, L.C., Rose, J.S., Selya, A., Mermelstein, R.J., 2012. The natural course of nicotine dependence symptoms among adolescent smokers. Nicotine Tob. Res. 14, 1445–1452.

Zhang, K., Wang, X., 2013. Maternal smoking and increased risk of sudden infant death syndrome: a meta-analysis. Legal Med. 15, 115–121.

Zoli, M., Le Novère, N., Hill, J.A., Changeux, J.-P., 1995. Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J. Neurosci. 15, 1912–1939.